Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,379 matching trials from the live ClinicalTrials.gov search.
Conditions
Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1)
Interventions
PF-07799933, binimetinib, cetuximab, midazolam, fluorouracil, leucovorin, oxaliplatin
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
31
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more
Conditions
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Lung Adenocarcinoma, Renal Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, Ovarian Cancer
Interventions
PY314, Combination Therapy: PY314 + Pembrolizumab
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 18 more
Conditions
Healthy Participants
Interventions
AZD2389, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Glendale, California
Conditions
Amyloidosis; Systemic
Interventions
AT-02, AT-02 (Placebo)
Drug · Other
Lead sponsor
Attralus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
6
States / cities
Overland Park, Kansas • Baltimore, Maryland • Kansas City, Missouri + 3 more
Conditions
Solid Tumor
Interventions
BDTX-189
Drug
Lead sponsor
Black Diamond Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Scottsdale, Arizona • Long Beach, California • Orange, California + 20 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study in Healthy Adults Evaluating PF-07202954

NCT04857437
Conditions
Non-Alcoholic Fatty Liver Disease, Liver Fibrosis
Interventions
PF-07202954 Repeat Dose, PF-07202954 Single Dose, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Bleeding
Interventions
60mg edoxaban, 180mg edoxaban, 50 IU/kg Beriplex P/N, 25 IU/kg Beriplex P/N, 10 IU/kg Beriplex P/N
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Healthy Participants, Alzheimer's Disease Dementia
Interventions
Emraclidine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
11
States / cities
Cypress, California • San Diego, California • Hialeah, Florida + 8 more
Conditions
Healthy Elderly, Parkinson Disease
Interventions
IkT-148009, Placebo
Drug
Lead sponsor
ABLi Therapeutics, Inc.
Industry
Eligibility
55 Years to 70 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Long Beach, California • Hallandale, Florida • Farmington Hills, Michigan + 1 more
Conditions
Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
Lomvastomig
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Conditions
Carcinoma, Non-small-Cell Lung
Interventions
Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
26
States / cities
La Jolla, California • Orange, California • Stanford, California + 21 more
Conditions
Cystic Fibrosis
Interventions
Observational
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
12 Years and older
Enrollment
452 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
38
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 31 more
Conditions
HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
Interventions
AVZO-021, Fulvestrant, Letrozole, AVZO-023
Drug
Lead sponsor
Avenzo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
16
States / cities
Los Angeles, California • New Haven, Connecticut • Orlando, Florida + 12 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects

NCT03672604
Conditions
Safety and Tolerability in Healthy Volunteers
Interventions
NLY01
Drug
Lead sponsor
Neuraly, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Pancreatic Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
Interventions
BTP-114
Drug
Lead sponsor
Placon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Sarasota, Florida • Boston, Massachusetts • St Louis, Missouri + 4 more
Conditions
Metastatic Colorectal Cancer
Interventions
SPLIT Abs, 203Pb-DOTAM, 212Pb-DOTAM
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
5
States / cities
Chicago, Illinois • St Louis, Missouri • Omaha, Nebraska + 2 more
Conditions
Glaucoma
Interventions
Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, Placebo eye drops
Drug · Procedure · Other
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Grand Junction, Colorado • Oklahoma City, Oklahoma • El Paso, Texas
Conditions
Neoplasms, Neoplasm Metastasis, Lymphoma
Interventions
LY3039478, Prednisone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Conditions
High Grade Glioma
Interventions
Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine, Ritonavir, Temozolomide, Focal Radiotherapy
Procedure · Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Conditions
Arthrofibrosis of Knee
Interventions
Losartan
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Healthy, Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
JNJ-67571244
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Boston, Massachusetts • Detroit, Michigan • Hackensack, New Jersey + 5 more
Conditions
Carcinoma, Ductal, Breast, Breast Cancer Female, Breast Neoplasm, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Stage IV Breast Cancer
Interventions
G1T48, Palbociclib
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Beverly Hills, California • Stanford, California • Chicago, Illinois + 3 more
Conditions
Hypoglycemia
Interventions
XOMA 358 single dose level A, XOMA 358 single dose level B, XOMA 358 single dose level C, XOMA 358 multiple dose level 1
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
Aurora, Colorado • Chicago, Illinois • Baltimore, Maryland + 2 more